Login
Rallybio Corp logo

Rallybio Corp

rallybio.com

Rallybio Corp (NASDAQ: RLYB) is a clinical-stage biopharmaceutical company focused on developing product candidates for rare and severe diseases. The company generates no product revenue and finances operations through equity sales, debt financings, collaborations, strategic alliances, and licensing arrangements, as disclosed in its 10-K filed March 16, 2026. As of FY2025, net cash used in operating activities was $29.8 million, down from $49.3 million in FY2024, reflecting reduced research and development and general and administrative spending. Investing activities provided $47.3 million in FY2025, primarily from maturities of highly-rated securities. Rallybio has limited financial resources and has concentrated development on a select set of product candidates. The company is incorporated in Delaware and led by Stephen Uden, M.D. as Chief Executive Officer and President, with Jonathan I. Lieber, M.B.A. as Chief Financial Officer and Steven Ryder, M.D. as Chief Medical Officer. As of the filing date, Rallybio had entered into a merger agreement with Candid, with pre-merger Rallybio equityholders expected to own approximately 3.65% of the combined company upon closing.

Products & Services

Clinical-stage product candidates targeting rare and severe diseases. Specific product names are not detailed in the provided filing excerpts.

Revenue Model

No product revenue as of the 10-K filed March 16, 2026. Operations are financed through equity issuances, debt financings, collaborations, strategic alliances, and licensing arrangements. The company holds no committed external funding source.

Customers & Markets

No commercial customers as of the filing date. Target end markets are patients with rare and severe diseases, subject to U.S. FDA approval and government reimbursement programs including Medicare and Medicaid.

Geographic Exposure

Primary operations in the United States. Subject to GDPR and UK GDPR data protection requirements, indicating some exposure to European regulatory frameworks.

Financial Snapshot

Revenue
TTM
$858.0K
Gross Margin
Last 4 Quarters
N/A
Net Income
TTM
-$7.817M
Current Assets
2026 Q1
Current Liabilities
2026 Q1
Current Ratio
2026 Q1
1292.03%
Total Assets
2026 Q1
Total Liabilities
2026 Q1
Book Value
2026 Q1
$50.28M
Cash
2026 Q1
P/E
Last 4 Quarters
N/A
Free Cash Flow
Last 4 Quarters
N/A

Stock Price

Loading...
Market Cap: $83.37 Million

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support